1. Home
  2. FAMI vs ENTO Comparison

FAMI vs ENTO Comparison

Compare FAMI & ENTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FAMI
  • ENTO
  • Stock Information
  • Founded
  • FAMI 2015
  • ENTO 2014
  • Country
  • FAMI China
  • ENTO United States
  • Employees
  • FAMI N/A
  • ENTO 2
  • Industry
  • FAMI Packaged Foods
  • ENTO Biotechnology: Pharmaceutical Preparations
  • Sector
  • FAMI Consumer Staples
  • ENTO Health Care
  • Exchange
  • FAMI Nasdaq
  • ENTO Nasdaq
  • Market Cap
  • FAMI 2.1M
  • ENTO 1.7M
  • IPO Year
  • FAMI 2018
  • ENTO 2016
  • Fundamental
  • Price
  • FAMI $1.64
  • ENTO $0.36
  • Analyst Decision
  • FAMI
  • ENTO
  • Analyst Count
  • FAMI 0
  • ENTO 0
  • Target Price
  • FAMI N/A
  • ENTO N/A
  • AVG Volume (30 Days)
  • FAMI 96.1K
  • ENTO 1.4M
  • Earning Date
  • FAMI 05-06-2025
  • ENTO 05-20-2025
  • Dividend Yield
  • FAMI N/A
  • ENTO N/A
  • EPS Growth
  • FAMI N/A
  • ENTO N/A
  • EPS
  • FAMI N/A
  • ENTO N/A
  • Revenue
  • FAMI $64,131,332.00
  • ENTO N/A
  • Revenue This Year
  • FAMI N/A
  • ENTO N/A
  • Revenue Next Year
  • FAMI N/A
  • ENTO N/A
  • P/E Ratio
  • FAMI N/A
  • ENTO N/A
  • Revenue Growth
  • FAMI N/A
  • ENTO N/A
  • 52 Week Low
  • FAMI $1.43
  • ENTO $0.19
  • 52 Week High
  • FAMI $11.28
  • ENTO $3.24
  • Technical
  • Relative Strength Index (RSI)
  • FAMI 40.76
  • ENTO 38.33
  • Support Level
  • FAMI $1.55
  • ENTO $0.38
  • Resistance Level
  • FAMI $1.98
  • ENTO $0.39
  • Average True Range (ATR)
  • FAMI 0.14
  • ENTO 0.04
  • MACD
  • FAMI 0.05
  • ENTO -0.00
  • Stochastic Oscillator
  • FAMI 29.17
  • ENTO 18.24

About FAMI Farmmi Inc.

Farmmi Inc is an investment holding company. Through its subsidiaries, it acts as a supplier of agricultural products. It is an agricultural technology enterprise focused on its supply chain platform by promoting edible mushroom products and agriculture technology. Its product offerings include tapioca, corn, red dates, shiitake mushrooms, mu er fungus, other edible fungi, and other agricultural products. Geographically, the company's products are sold in China, Southeast Asia, Japan, North America, Europe, and the Middle East under the Forasen and Farmmi brands.

About ENTO Entero Therapeutics Inc. Common Stock

Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: